Combined chemoradiation therapy for limited-stage small-cell lung cancer

Ming Teng, Hak Choy, David S Ettinger

Research output: Contribution to journalArticle

Abstract

After nearly 4 decades of use in treating small-cell lung cancer (SCLC), thoracic radiation has become integral to the management of limited-stage disease. Many prospective randomized trials have demonstrated that adding thoracic radiation therapy to chemotherapy improves locoregional control and survival at 3 and 5 years. This has resulted in a greater appreciation of the role of thoracic radiation in the treatment of SCLC. Currently, the most commonly used regimens incorporate concurrent administration of cisplatin (Platinol) and etoposide (VePesid) chemotherapy and radiation doses of 45 Gy given over 5 weeks. However, issues concerning timing, volume, and dose fractionation remain to be resolved.

Original languageEnglish (US)
Pages (from-to)107-115
Number of pages9
JournalOncology
Volume13
Issue number10 SUPPL. 5
StatePublished - 1999

Fingerprint

Small Cell Lung Carcinoma
Thorax
Etoposide
Radiation
Cisplatin
Dose Fractionation
Drug Therapy
Radiotherapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Combined chemoradiation therapy for limited-stage small-cell lung cancer. / Teng, Ming; Choy, Hak; Ettinger, David S.

In: Oncology, Vol. 13, No. 10 SUPPL. 5, 1999, p. 107-115.

Research output: Contribution to journalArticle

Teng, M, Choy, H & Ettinger, DS 1999, 'Combined chemoradiation therapy for limited-stage small-cell lung cancer', Oncology, vol. 13, no. 10 SUPPL. 5, pp. 107-115.
Teng, Ming ; Choy, Hak ; Ettinger, David S. / Combined chemoradiation therapy for limited-stage small-cell lung cancer. In: Oncology. 1999 ; Vol. 13, No. 10 SUPPL. 5. pp. 107-115.
@article{ad0d469535424d17b2518e8f2a012d17,
title = "Combined chemoradiation therapy for limited-stage small-cell lung cancer",
abstract = "After nearly 4 decades of use in treating small-cell lung cancer (SCLC), thoracic radiation has become integral to the management of limited-stage disease. Many prospective randomized trials have demonstrated that adding thoracic radiation therapy to chemotherapy improves locoregional control and survival at 3 and 5 years. This has resulted in a greater appreciation of the role of thoracic radiation in the treatment of SCLC. Currently, the most commonly used regimens incorporate concurrent administration of cisplatin (Platinol) and etoposide (VePesid) chemotherapy and radiation doses of 45 Gy given over 5 weeks. However, issues concerning timing, volume, and dose fractionation remain to be resolved.",
author = "Ming Teng and Hak Choy and Ettinger, {David S}",
year = "1999",
language = "English (US)",
volume = "13",
pages = "107--115",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 5",

}

TY - JOUR

T1 - Combined chemoradiation therapy for limited-stage small-cell lung cancer

AU - Teng, Ming

AU - Choy, Hak

AU - Ettinger, David S

PY - 1999

Y1 - 1999

N2 - After nearly 4 decades of use in treating small-cell lung cancer (SCLC), thoracic radiation has become integral to the management of limited-stage disease. Many prospective randomized trials have demonstrated that adding thoracic radiation therapy to chemotherapy improves locoregional control and survival at 3 and 5 years. This has resulted in a greater appreciation of the role of thoracic radiation in the treatment of SCLC. Currently, the most commonly used regimens incorporate concurrent administration of cisplatin (Platinol) and etoposide (VePesid) chemotherapy and radiation doses of 45 Gy given over 5 weeks. However, issues concerning timing, volume, and dose fractionation remain to be resolved.

AB - After nearly 4 decades of use in treating small-cell lung cancer (SCLC), thoracic radiation has become integral to the management of limited-stage disease. Many prospective randomized trials have demonstrated that adding thoracic radiation therapy to chemotherapy improves locoregional control and survival at 3 and 5 years. This has resulted in a greater appreciation of the role of thoracic radiation in the treatment of SCLC. Currently, the most commonly used regimens incorporate concurrent administration of cisplatin (Platinol) and etoposide (VePesid) chemotherapy and radiation doses of 45 Gy given over 5 weeks. However, issues concerning timing, volume, and dose fractionation remain to be resolved.

UR - http://www.scopus.com/inward/record.url?scp=0033212637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033212637&partnerID=8YFLogxK

M3 - Article

C2 - 10550834

AN - SCOPUS:0033212637

VL - 13

SP - 107

EP - 115

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 SUPPL. 5

ER -